The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
The DOI matches its Crossref record; 313 of the 323 references it cites were found in a registry or an index.
Abstract
The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic alpha-cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed. Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving alpha-cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in patients with T2DM elevated plasma glucagon levels have been observed in the fasting state, and defective suppression of glucagon secretion exists in the postprandial state, resulting in elevated plasma glucagon levels (7)”
From Mathematical Model of Glucagon Kinetics for the Assessment of Insulin-Mediated Glucagon Inhibition During an Oral Glucose Tolerance Test (2021) · cites this paper as [7]
In the citing paper
“dysregulated α-cell release of glucagon, manifest as increased fasting glucagon concentrations and a failure to adequately suppress glucagon release following meal ingestion, contributes to the development of hyperglycaemia34.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [34]
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532
Immunoassay of endogenous plasma insulin in man
Yalow, R. S., & Berson, S. A. (1960) · Journal of Clinical Investigation · doi:10.1172/jci104130 · Cited by 3,041
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Methods of Hormone Radioimmunoassay
(1978) · Elsevier eBooks · doi:10.1016/b978-0-123-79260-0.x5001-8 · Cited by 2,077
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
(2004) · doi:10.1016/s0092-8674(04)00452-0 · Cited by 1,356
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Lambeir, A.-M., Durinx, C., Scharpé, S., & De Meester, I. (2003) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/713609354 · Cited by 955
Glucagon and regulation of glucose metabolism
Jiang, G., & Zhang, B. B. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00492.2002 · Cited by 905
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Studies of pancreatic alpha cell function in normal and diabetic subjects
Unger, R. H., Aguilar-Parada, E., Müller, W. A., & Eisentraut, A. M. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106297 · Cited by 837
Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, K., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0493156 · Cited by 822
Nauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Substrate Turnover during Prolonged Exercise in Man
Ahlborg, G., Felig, P., Hagenfeldt, L., Hendler, R., & Wahren, J. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107645 · Cited by 786
Magnusson, I., Rothman, D. L., Katz, L. D., Shulman, R. G., & Shulman, G. I. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115997 · Cited by 757
(1922) · PubMed · Cited by 753
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Gerich, J. E., Langlois, M., Noacco, C., Karam, J. H., & Forsham, P. H. (1973) · Science · doi:10.1126/science.182.4108.171 · Cited by 688
Self-citation(1997) · Diabetes reviews · Cited by 671
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
Augeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut
Holst, J. J., Ørskov, C., Vagn Nielsen, O., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Self-citationNauck, M. A., Heimesaat, M. M., Behle, K., Holst, J. J., Nauck, M. S., Ritzel, R., Hüfner, M., & Schmiegel, W. H. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8355 · Cited by 605
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599
Mitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595
Self-citationExon duplication and divergence in the human preproglucagon gene
Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593
β-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diab.40.2.166 · Cited by 585
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Weckbecker, G., Lewis, I., Albert, R., Schmid, H. A., Hoyer, D., & Bruns, C. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1255 · Cited by 559
Kolterman, O. G., Buse, J. B., Fineman, M. S., Gaines, E., Heintz, S., Bicsak, T. A., Taylor, K., Kim, D., Aisporna, M., Wang, Y., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021545 · Cited by 552
Pancreatic Glucagon Secretion in Normal and Diabetic Subjects
Aguilar-Parada, E., Eisentraut, A. M., & Unger, R. H. (1969) · The American Journal of the Medical Sciences · doi:10.1097/00000441-196906000-00008 · Cited by 535
HERMAN, G., STEVENS, C., VANDYCK, K., BERGMAN, A., YI, B., DESMET, M., SNYDER, K., HILLIARD, D., TANEN, M., & TANAKA, W. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.09.002 · Cited by 519
Somatostatin: Hypothalamic Inhibitor of the Endocrine Pancreas
Koerker, D. J., Ruch, W., Chideckel, E., Palmer, J., Goodner, C. J., Ensinck, J., & Gale, C. C. (1974) · Science · doi:10.1126/science.184.4135.482 · Cited by 519
DeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515
Rosenstock, J., Brazg, R., Andryuk, P. J., Lu, K., & Stein, P. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.10.007 · Cited by 514
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Herman, G. A., Bergman, A., Stevens, C., Kotey, P., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrodter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495
Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes
Lankas, G. R., Leiting, B., Roy, R. S., Eiermann, G. J., Beconi, M. G., Biftu, T., Chan, C.-C., Edmondson, S., Feeney, W. P., He, H., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2988 · Cited by 491
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2003.10.028 · Cited by 457
Bosi, E., Camisasca, R. P., Collober, C., Rochotte, E., & Garber, A. J. (2007) · Diabetes Care · doi:10.2337/dc06-1732 · Cited by 447
Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2
Furuta, M., Yano, H., Zhou, A., Rouillé, Y., Holst, J. J., Carroll, R., Ravazzola, M., Orci, L., Furuta, H., & Steiner, D. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6646 · Cited by 431
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Degn, K. B., Juhl, C. B., Sturis, J., Jakobsen, G., Brock, B., Chandramouli, V., Rungby, J., Landau, B. R., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1187 · Cited by 427
Ahrén, B., Simonsson, E., Larsson, H., Landin-Olsson, M., Torgeirsson, H., Jansson, P.-A., Sandqvist, M., Båvenholm, P., Efendic, S., Eriksson, J. W., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.5.869 · Cited by 421
Predominant Role of Gluconeogenesis in Increased Hepatic Glucose Production in NIDDM
Consoli, A., Nurjhan, N., Capani, F., & Gerich, J. (1989) · Diabetes · doi:10.2337/diab.38.5.550 · Cited by 406
Self-citationNatali, A., & Ferrannini, E. (2006) · Diabetologia · doi:10.1007/s00125-006-0141-7 · Cited by 377
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean
Yamada, M., Miyakawa, T., Duttaroy, A., Yamanaka, A., Moriguchi, T., Makita, R., Ogawa, M., Chou, C. J., Xia, B., Crawley, J. N., et al. (2001) · Nature · doi:10.1038/35065604 · Cited by 373
Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Wahren, J., Felig, P., & Hagenfeldt, L. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108375 · Cited by 368
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Self-citationGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354
Self-citationTHE EFFECTS OF TOTAL STARVATION UPON THE LEVELS OF CIRCULATING GLUCAGON AND INSULIN IN MAN*
Unger, R. H., Eisentraut, A. M., & Madison, L. L. (1963) · Journal of Clinical Investigation · doi:10.1172/jci104788 · Cited by 345
Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336
Self-citationRegulation of Pancreatic Insulin and Glucagon Secretion
Gerich, J. E., Charles, M. A., & Grodsky, G. M. (1976) · Annual Review of Physiology · doi:10.1146/annurev.ph.38.030176.002033 · Cited by 332
Self-citationPospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
REAVEN, G. M., CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & JASPAN, J. B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-106 · Cited by 326
Ørskov, C., Wettergren, A., & Holst, J. J. (1993) · Diabetes · doi:10.2337/diab.42.5.658 · Cited by 325
Gastaldelli, A., Baldi, S., Pettiti, M., Toschi, E., Camastra, S., Natali, A., Landau, B. R., & Ferrannini, E. (2000) · Diabetes · doi:10.2337/diabetes.49.8.1367 · Cited by 320
Contribution of Abnormal Muscle and Liver Glucose Metabolism to Postprandial Hyperglycemia in NIDDM
Mitrakou, A., Kelley, D., Veneman, T., Jenssen, T., Pangburn, T., Reilly, J., & Gerich, J. (1990) · Diabetes · doi:10.2337/diab.39.11.1381 · Cited by 317
Self-citationMeier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Madsbad, S., Schmitz, O., Ranstam, J., Jakobsen, G., Matthews, D. R., & on behalf of the NN2211-1310 International Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1335 · Cited by 312
Baron, A. D., Schaeffer, L., Shragg, P., & Kolterman, O. G. (1987) · Diabetes · doi:10.2337/diab.36.3.274 · Cited by 308
Møller, L. N., Stidsen, C. E., Hartmann, B., & Holst, J. J. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(03)00235-9 · Cited by 307
Glucagon and the a Cell: Physiology and Pathophysiology(First of Two Parts)
Unger, R. H., & Orci, L. (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042504 · Cited by 299
Franklin, I., Gromada, J., Gjinovci, A., Theander, S., & Wollheim, C. B. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1808 · Cited by 299
DeFronzo, R. A., Ferrannini, E., Hendler, R., Wahren, J., & Felig, P. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.10.5173 · Cited by 296
GLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON*
Unger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104357 · Cited by 285
Intra-islet insulin suppresses glucagon release via GABA-GABAA receptor system
Xu, E., Kumar, M., Zhang, Y., Ju, W., Obata, T., Zhang, N., Liu, S., Wendt, A., Deng, S., Ebina, Y., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2005.11.015 · Cited by 283
Elbrønd, B., Jakobsen, G., Larsen, S., Agersø, H., Jensen, L. B., Rolan, P., Sturis, J., Hatorp, V., & Zdravkovic, M. (2002) · Diabetes Care · doi:10.2337/diacare.25.8.1398 · Cited by 279
Dipeptidyl Peptidase IV Inhibitors for the Treatment of Diabetes
Weber, A. E. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030628v · Cited by 278
Unger, R. H., Eisentraut, A. M., McCall, M. S., & Madison, L. L. (1962) · Journal of Clinical Investigation · doi:10.1172/jci104525 · Cited by 278
Alpha cell function in health and disease: influence of glucagon-like peptide-1
Dunning, B. E., Foley, J. E., & Ahrén, B. (2005) · Diabetologia · doi:10.1007/s00125-005-1878-0 · Cited by 271
Self-citationComparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
Garber, A. J., Schweizer, A., Baron, M. A., Rochotte, E., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00684.x · Cited by 268
Mortimer, C. H., Carr, D., Lind, T., Bloom, S. R., Mallinson, C. N., Schally, A. V., Tunbridge, W. M. G., Yeomans, L., Coy, D. H., Kastin, A., et al. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92903-1 · Cited by 268
Bergman, A. J., Stevens, C., Zhou, Y., Yi, B., Laethem, M., De Smet, M., Snyder, K., Hilliard, D., Tanaka, W., Zeng, W., et al. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.015 · Cited by 265
Juhl, C. B., Hollingdal, M., Sturis, J., Jakobsen, G., Agersø, H., Veldhuis, J., Pørksen, N., & Schmitz, O. (2002) · Diabetes · doi:10.2337/diabetes.51.2.424 · Cited by 264
Influence of Glucocorticoids on Glucagon Secretion and Plasma Amino Acid Concentrations in Man
Wise, J. K., Hendler, R., & Felig, P. (1973) · Journal of Clinical Investigation · doi:10.1172/jci107473 · Cited by 256
Pharmacological Agents That Directly Modulate Insulin Secretion
Doyle, M. E., & Egan, J. M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.1.7 · Cited by 256
Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Degn, K. B., Brock, B., Juhl, C. B., Djurhuus, C. B., Grubert, J., Kim, D., Han, J., Taylor, K., Fineman, M., & Schmitz, O. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2397 · Cited by 254
Hyperglucagonemia and Blood Glucose Regulation in Normal, Obese and Diabetic Subjects
Sherwin, R. S., Fisher, M., Hendler, R., & Felig, P. (1976) · New England Journal of Medicine · doi:10.1056/nejm197602262940901 · Cited by 252
Cherrington, A. D., Chiasson, J. L., Liljenquist, J. E., Jennings, A. S., Keller, U., & Lacy, W. W. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108596 · Cited by 249
Assessing Insulin Secretion by Modeling in Multiple-Meal Tests
Mari, A., Tura, A., Gastaldelli, A., & Ferrannini, E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s221 · Cited by 248
Ristic, S., Byiers, S., Foley, J., & Holmes, D. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00539.x · Cited by 248
Balas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., He, Y.-L., Darland, C., Holst, J. J., Deacon, C. F., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1882 · Cited by 243
Self-citationThe importance of the β-cell in the pathogenesis of type 2 diabetes mellitus
Kahn, S. E. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00336-3 · Cited by 242
Kaestner, K. H., Katz, J., Liu, Y., Drucker, D. J., & Schutz, G. (1999) · Genes & Development · doi:10.1101/gad.13.4.495 · Cited by 241
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.1.87 · Cited by 237
The Banting Memorial Lecture 1975: Diabetes and the Alpha Cell
Unger, R. H. (1976) · Diabetes · doi:10.2337/diab.25.2.136 · Cited by 234
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., Brownsey, R., Parkhouse, W., Finegood, D. T., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.943 · Cited by 232
GLP-1 Receptor Agonists and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes
Ahrén, B., & Schmitz, O. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826178 · Cited by 224
Proglucagon is processed to glucagon by prohormone convertase PC2 in alpha TC1-6 cells.
Rouillé, Y., Westermark, G., Martin, S. K., & Steiner, D. F. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.8.3242 · Cited by 221
Hyperglucagonemia in diabetic ketoacidosis
Müller, W. A., Faloona, G. R., & Unger, R. H. (1973) · The American Journal of Medicine · doi:10.1016/0002-9343(73)90083-1 · Cited by 220
Sloop, K. W., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420911 · Cited by 219
Dejager, S., Razac, S., Foley, J., & Schweizer, A. (2007) · Hormone and Metabolic Research · doi:10.1055/s-2007-970422 · Cited by 211
Ritzel, R., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 210
Petersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 209
Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 209
Effects of Starvation on Plasma Pancreatic Glucagon in Normal Man
Aguilar-Parada, E., Eisentraut, A. M., & Unger, R. H. (1969) · Diabetes · doi:10.2337/diab.18.11.717 · Cited by 204
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
Drucker, D. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/eoid.12.1.87.21250 · Cited by 204
Liang, Y., Osborne, M. C., Monia, B. P., Bhanot, S., Gaarde, W. A., Reed, C., She, P., Jetton, T. L., & Demarest, K. T. (2004) · Diabetes · doi:10.2337/diabetes.53.2.410 · Cited by 202
Ohneda, A., Parada, E., Eisentraut, A. M., & Unger, R. H. (1968) · Journal of Clinical Investigation · doi:10.1172/jci105916 · Cited by 200
Duttaroy, A., Zimliki, C. L., Gautam, D., Cui, Y., Mears, D., & Wess, J. (2004) · Diabetes · doi:10.2337/diabetes.53.7.1714 · Cited by 199
Gerich, J. E., Lorenzi, M., Bier, D. M., Tsalikian, E., Schneider, V, Karam, J. H., & Forsham, P. H. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108364 · Cited by 198
Self-citationWestphal, C. H., Muller, L., Zhou, A., Zhu, X., Bonner-Weir, S., Schambelan, M., Steiner, D. F., Lindberg, I., & Leder, P. (1999) · Cell · doi:10.1016/s0092-8674(00)80579-6 · Cited by 196
Deacon, C. F., Ahrén, B., & Holst, J. J. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1091 · Cited by 194
Pratley, R., Jauffret-Kamel, S., Galbreath, E., & Holmes, D. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-944546 · Cited by 194
Type 2 diabetes—Therapy with dipeptidyl peptidase IV inhibitors
Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.05.010 · Cited by 192
Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190
On the physiology of GIP and GLP-1
Holst, J. J. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826158 · Cited by 189
Furuta, M., Carroll, R., Martin, S., Swift, H. H., Ravazzola, M., Orci, L., & Steiner, D. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.6.3431 · Cited by 187
GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice
Hansotia, T., & Drucker, D. J. (2005) · Regulatory Peptides · doi:10.1016/j.regpep.2004.07.019 · Cited by 183
Pancreatic Extracts in the Treatment of Diabetes Mellitus: Preliminary Report.
Banting, F., BEST, C. H., Collip, J. B., et al. (1962) · PubMed · Cited by 181
Potent, orally absorbed glucagon receptor antagonists
de Laszlo, S. E., Hacker, C., Li, B., Kim, D., MacCoss, M., Mantlo, N., Pivnichny, J. V., Colwell, L., Koch, G. E., Cascieri, M. A., et al. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00081-5 · Cited by 169
Liljenquist, J. E., Mueller, G. L., Cherrington, A. D., Keller, U., Chiasson, J.-L., Perry, J. M., Lacy, W. W., & Rabinowitz, D. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108649 · Cited by 168
The Hepatocyte Nuclear Factor 3 (HNF3 or FOXA) Family in Metabolism
Kaestner, K. H. (2000) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00271-x · Cited by 168
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diab.43.3.403 · Cited by 167
Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes
Meneilly, G. S., Cheung, E., & Tuokko, H. (1994) · Diabetes · doi:10.2337/diabetes.43.3.403 · Cited by 167
Hyperglycemia of Diabetic Rats Decreased by a Glucagon Receptor Antagonist
Johnson, D. G., Goebel, C. U., Hruby, V. J., Bregman, M. D., & Trivedi, D. (1982) · Science · doi:10.1126/science.6278587 · Cited by 166
Sudre, B., Broqua, P., White, R. B., Ashworth, D., Evans, D. M., Haigh, R., Junien, J.-L., & Aubert, M. L. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1461 · Cited by 165
Severe Defect in Proglucagon Processing in Islet A-cells of Prohormone Convertase 2 Null Mice
Furuta, M., Zhou, A., Webb, G., Carroll, R., Ravazzola, M., Orci, L., & Steiner, D. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103362200 · Cited by 164
Impact of lack of suppression of glucagon on glucose tolerance in humans
Shah, P., Basu, A., Basu, R., & Rizza, R. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.2.e283 · Cited by 164
Gautier, J., Fetita, S., Sobngwi, E., & Salaün-Martin, C. (2005) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70190-8 · Cited by 163
Glycemic Control in Mice with Targeted Disruption of the Glucagon Receptor Gene
Parker, J. C., Andrews, K. M., Allen, M. R., Stock, J. L., & McNeish, J. D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6265 · Cited by 162
The role of aminogenic glucagon secretion in blood glucose homeostasis
Unger, R. H., Ohneda, A., Aguilar-Parada, E., & Eisentraut, A. M. (1969) · Journal of Clinical Investigation · doi:10.1172/jci106039 · Cited by 158
Raju, B., & Cryer, P. E. (2005) · Diabetes · doi:10.2337/diabetes.54.3.757 · Cited by 155
PURIFICATION AND CRYSTALLIZATION OF GLUCAGON
Staub, A., Sinn, L., & Behrens, O. K. (1955) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)70910-1 · Cited by 153
Banting lecture 1990. Beta-cells in type II diabetes mellitus
Porte, D. (1991) · Diabetes · doi:10.2337/diabetes.40.2.166 · Cited by 150
Therapeutic Approaches to Preserve Islet Mass in Type 2 Diabetes
Baggio, L. L., & Drucker, D. J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.110104.115624 · Cited by 149
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
Mest, H. ‐., & Mentlein, R. (2005) · Diabetologia · doi:10.1007/s00125-005-1707-5 · Cited by 148
Brand, C. L., Rolin, B., Jørgensen, P. N., Svendsen, I., Kristensen, J. S., & Holst, J. J. (1994) · Diabetologia · doi:10.1007/bf00400461 · Cited by 146
Postprandial Suppression of Glucagon Secretion Depends on Intact Pulsatile Insulin Secretion
Meier, J. J., Kjems, L. L., Veldhuis, J. D., Lefèbvre, P., & Butler, P. C. (2006) · Diabetes · doi:10.2337/diabetes.55.04.06.db05-1449 · Cited by 144
Murlin, J. R., Clough, H. D., Gibbs, C. B. F., & Stokes, A. M. (1923) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)85619-8 · Cited by 141
Chen, M., Gavrilova, O., Zhao, W.-Q., Nguyen, A., Lorenzo, J., Shen, L., Nackers, L., Pack, S., Jou, W., & Weinstein, L. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24196 · Cited by 141
Pospisilik, J. A., Stafford, S. G., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2677 · Cited by 138
Post-prandial hyperglycemia. post-prandial hyperglycemia and diabetes.
Gin, H., & Rigalleau, V. (2000) · PubMed · Cited by 135
The Vascular Order of Islet Cellular Perfusion in the Human Pancreas
Stagner, J. I., & Samols, E. (1992) · Diabetes · doi:10.2337/diab.41.1.93 · Cited by 135
Chiasson, J. L., Liljenquist, J. E., Sinclair-Smith, B. C., & Lacy, W. W. (1975) · Diabetes · doi:10.2337/diab.24.6.574 · Cited by 133
Felig, P., Wahren, J., & Hendler, R. (1976) · Journal of Clinical Investigation · doi:10.1172/jci108523 · Cited by 131
Butler, P. C., & Rizza, R. A. (1991) · Diabetes · doi:10.2337/diab.40.1.73 · Cited by 129
Yang, L., Berk, S. C., Rohrer, S. P., Mosley, R. T., Guo, L., Underwood, D. J., Arison, B. H., Birzin, E. T., Hayes, E. C., Mitra, S. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10836 · Cited by 129
Exendin-4 Normalized Postcibal Glycemic Excursions in Type 1 Diabetes
Dupré, J., Behme, M. T., & McDonald, T. J. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032001 · Cited by 127
Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist
Unson, C. G., Gurzenda, E. M., & Merrifield, R. B. (1989) · Peptides · doi:10.1016/0196-9781(89)90010-7 · Cited by 126
Hughes, T. E., Mone, M. D., Russell, M. E., Weldon, S. C., & Villhauer, E. B. (1999) · Biochemistry · doi:10.1021/bi990852f · Cited by 126
Gerich, J. E., Lorenzi, M., Hane, S., Gustafson, G. M., Guillemin, R., & Forsham, P. H. (1975) · Metabolism · doi:10.1016/0026-0495(75)90018-9 · Cited by 122
Self-citationDistribution of immunoassayable glucagon in gastrointestinal tissues
Unger, R. H., Ketterer, H., & Eisentraut, A. M. (1966) · Metabolism · doi:10.1016/0026-0495(66)90156-9 · Cited by 122
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Dunning, B. E., Mangold, B. L., Mone, M. D., Russell, M. E., Weldon, S. C., & Hughes, T. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025522z · Cited by 121
Self-citationGastaldelli, A., Miyazaki, Y., Pettiti, M., Buzzigoli, E., Mahankali, S., Ferrannini, E., & DeFronzo, R. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031941 · Cited by 117
Acute and Chronic Effects of the Incretin Enhancer Vildagliptin in Insulin-Resistant Rats
Burkey, B. F., Li, X., Bolognese, L., Balkan, B., Mone, M. D., Russell, M., Hughes, T. E., & Wang, P. R. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087064 · Cited by 115
GLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 113
Drucker, D. (2001) · Current Pharmaceutical Design · doi:10.2174/1381612013397401 · Cited by 113
Hope, K. M., Tran, P. O. T., Zhou, H., Oseid, E., Leroy, E., & Robertson, R. P. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1488 · Cited by 112
Glucose homeostasis during prolonged suppression of glucagon and insulin secretion by somatostatin.
Sherwin, R. S., Hendler, R., DeFronzo, R., Wahren, J., & Felic, P. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.1.348 · Cited by 110
Intra-Islet Somatostatin Regulates Glucagon Release via Type 2 Somatostatin Receptors in Rats
Cejvan, K., Coy, D. H., & Efendic, S. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1176 · Cited by 110
Substituted Imidazoles as Glucagon Receptor Antagonists
Chang, L. L., Sidler, K. L., Cascieri, M. A., de Laszlo, S. E., Koch, G. E., Li, B., MacCoss, M., Mantlo, N. B., O’Keefe, S. J., Pang, M., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00498-x · Cited by 109
Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes
Woerle, H. J., Szoke, E., Meyer, C., Dostou, J. M., Wittlin, S. D., Gosmanov, N. R., Welle, S. L., & Gerich, J. E. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00529.2004 · Cited by 109
Self-citationA Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Qureshi, S. A., Rios Candelore, M., Xie, D., Yang, X., Tota, L. M., Ding, V. D.-H., Li, Z., Bansal, A., Miller, C., Cohen, S. M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3267 · Cited by 109
Bolli, G. B., Tsalikian, E., Haymond, M. W., Cryer, P. E., & Gerich, J. E. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111359 · Cited by 108
Self-citationSynthetic peptide antagonists of glucagon.
Unson, C. G., Andreu, D., Gurzenda, E. M., & Merrifield, R. B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.12.4083 · Cited by 102
Magnusson, I., Rothman, D. L., Gerard, D. P., Katz, L. D., & Shulman, G. I. (1995) · Diabetes · doi:10.2337/diab.44.2.185 · Cited by 97
Brand, C. L., Jørgensen, P. N., Svendsen, I., & Hoist, J. J. (1996) · Diabetes · doi:10.2337/diab.45.8.1076 · Cited by 94
Wiedeman, P. E., & Trevillyan, J. M. (2003) · PubMed · Cited by 94
Madsen, P., Knudsen, L. B., Wiberg, F. C., & Carr, R. D. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9810304 · Cited by 92
Characterization of a Novel, Non-peptidyl Antagonist of the Human Glucagon Receptor
Cascieri, M. A., Koch, G. E., Ber, E., Sadowski, S. J., Louizides, D., de Laszlo, S. E., Hacker, C., Hagmann, W. K., MacCoss, M., Chicchi, G. G., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.13.8694 · Cited by 92
Basu, A., Alzaid, A., Dinneen, S., Caumo, A., Cobelli, C., & Rizza, R. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118678 · Cited by 90
Webb, G. C., Akbar, M. S., Zhao, C., Swift, H. H., & Steiner, D. F. (2002) · Diabetes · doi:10.2337/diabetes.51.2.398 · Cited by 89
Glucose-regulated Glucagon Secretion Requires Insulin Receptor Expression in Pancreatic α-Cells
Diao, J., Asghar, Z., Chan, C. B., & Wheeler, M. B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m506276200 · Cited by 88
Madsen, P., Ling, A. L., Plewe, M. B., Sams, C. K., Knudsen, L. B., Sidelmann, U. G., Ynddal, L., Brand, C. L., Andersen, B., Murphy, D. E., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0208572 · Cited by 87
Basu, R., Schwenk, W. F., & Rizza, R. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00549.2003 · Cited by 87
Beshara, S., Lundqvist, H., Sundin, J., Lubberink, M., Tolmachev, V., Valind, S., Antoni, G., Långström, B., & Danielson, B. G. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01179.x · Cited by 86
Glucagon Radioimmunoassay Using Antiserum 30K: Interference by Plasma
Weir, G., Turner, R., & Martin, D. (1973) · Hormone and Metabolic Research · doi:10.1055/s-0028-1093958 · Cited by 86
Insulin-Glucagon Relationships in the Defense Against Hypoglycemia
Unger, R. H. (1983) · Diabetes · doi:10.2337/diab.32.6.575 · Cited by 85
2-cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV
Ashworth, D. M., Atrash, B., Baker, G. R., Baxter, A., Jenkins, P. D., Jones, D. M., & Szelke, M. (1996) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/0960-894x(96)00190-4 · Cited by 85
Similar Dose Responsiveness of Hepatic Glycogenolysis and Gluconeogenesis to Glucagon In Vivo
Stevenson, R. W., Steiner, K. E., Davis, M. A., Hendrick, G. K., Williams, P. E., Lacy, W. W., Brown, L., Donahue, P., Lacy, D. B., & Cherrington, A. D. (1987) · Diabetes · doi:10.2337/diab.36.3.382 · Cited by 83
Ryan, A. S., Egan, J. M., Habener, J. F., & Elahi, D. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4988 · Cited by 81
Henkel, E., Menschikowski, M., Koehler, C., Leonhardt, W., & Hanefeld, M. (2005) · Metabolism · doi:10.1016/j.metabol.2005.03.024 · Cited by 81
Ludvik, B., Nolan, J. J., Roberts, A., Baloga, J., Joyce, M., Bell, J. M., & Olefsky, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119775 · Cited by 80
Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon
Rouillé, Y., Bianchi, M., Irminger, J.-C., & Halban, P. A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)00892-2 · Cited by 80
From Presumed Benefit to Potential Harm — Hormone Therapy and Heart Disease
Herrington, D. M., & Howard, T. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038108 · Cited by 80
Sørensen, H., Brand, C. L., Neschen, S., Holst, J. J., Fosgerau, K., Nishimura, E., & Shulman, G. I. (2006) · Diabetes · doi:10.2337/db06-0222 · Cited by 80
The Role of Dipeptidyl Peptidase IV (DP IV) Enzymatic Activity in T Cell Activation and Autoimmunity
Reinhold, D., Kähne, T., Steinbrecher, A., Wrenger, S., Neubert, K., ANSORGE, S., & Brocke, S. (2002) · Biological Chemistry · doi:10.1515/bc.2002.123 · Cited by 79
Effect of Insulin on the Exaggerated Glucagon Response to Arginine Stimulation in Diabetes Mellitus
Raskin, P., Aydin, I., & Unger, R. H. (1976) · Diabetes · doi:10.2337/diab.25.3.227 · Cited by 78
Über das Glukagon (die hyperglykämisierende Substanz des Pankreas)
Burger, M. M., & Brandt, W. (1935) · Clinical and Experimental Medicine · doi:10.1007/bf02595511 · Cited by 78
GLP-1 inhibition of pancreatic islet cell apoptosis
Urusova, I. A., Farilla, L., Hui, H., D'Amico, E., & Perfetti, R. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2003.11.006 · Cited by 77
Research works printed but not linked: 9
- 2005, Sandostatin LAR depot (octreotide acetate for injectable suspension).
- 2005, Byetta (exenatide injection)[prescribing information].
- Pratley, 2005, Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus., Sci Med, 10, 13
- Villhauer, 2001, DPP-IV inhibition and therapeutic potential., Annu Rep Med Chem, 36, 191
- Balas, J Clin Endocrinol Metab
- Dejager, Horm Metab Res
- Bosi, Diabetes Care
- Rosenstock, Diabetes Obes Metab
- Garber, Diabetes Obes Metab
Cited by
Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future
Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62154-6 · Cited by 1,743
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Pancreatic β‐cell mass in European subjects with type 2 diabetes
Rahier, J., Guiot, Y., Goebbels, R. M., Sempoux, C., & Henquin, J. C. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00969.x · Cited by 756
“This relative hyperglucagonaemia aggravates the consequences of their relative hypoinsulinaemia by activating glucose production in the liver [8–10].”
BackgroundEvidence of β-Cell Dedifferentiation in Human Type 2 Diabetes
Cinti, F., Bouchi, R., Kim-Muller, J. Y., Ohmura, Y., Sandoval, P. R., Masini, M., Marselli, L., Suleiman, M., Ratner, L. E., Marchetti, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2860 · Cited by 550
Dayeh, T., Volkov, P., Salö, S., Hall, E., Nilsson, E., Olsson, A. H., Kirkpatrick, C. L., Wollheim, C. B., Eliasson, L., Rönn, T., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004160 · Cited by 523
“Since both decreased insulin and increased glucagon secretion from pancreatic islets are known to contribute to hyperglycemia in patients with T2D [49], we investigated whether the identified candidate genes also affect glucagon secretion in clonal a-cells.”
Metadata
- Authors
- Dunning, B. E., & Gerich, J. E.
- Affiliations
- PharmaWrite, Princeton, New Jersey 08540
- University of Rochester Medicine (US)
- Corresponding author
- Gerich, John E.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2007-04-04
- Volume
- 28
- Issue
- 3
- Pages
- 253-283
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W2088987697
- Cited by
- 369
- References
- 323
- Citations by year
- 2026: 6 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 20 · 2020: 15 · 2019: 21 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 23 · 2014: 24 · 2013: 27 · 2012: 27
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- Sanofi
- University of Rochester
- Kowa Company
- Eisai
- Novo Nordisk
- Medical Center, University of Rochester
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- glucagon, alpha cells, type 2 diabetes, fasting hyperglycemia, postprandial hyperglycemia, hyperglucagonemia, glucagon receptor antagonists, somatostatin, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon secretion, glycemic control, glucoregulation
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Fasting, Glucagon, Humans, Hyperglycemia, Receptors, Glucagon, Postprandial Period, Glucagon-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.